-
Twenty–second listing of 2021 on Borsa Italiana’s AIM Italia
-
Ulisse Biomed S.p.A. brings the total number of companies listed on Borsa Italiana’s AIM Italia to 153
-
Total placement volume of the offering equal to €5 million with listing
Milan – 6 August 2021 – Borsa Italiana, part of the Euronext Group, today congratulates Ulisse Biomed S.p.A. on its listing on Borsa Italiana’s AIM Italia.
Ulisse Biomed S.p.A. is a healthcare biotech company operating in the diagnostics, theranostics and therapeutics.
Ulisse Biomed S.p.A. is the twenty–second company to list since the beginning of the year on Borsa Italiana’s market dedicated to small and medium-sized companies and brings the total number of firms currently listed on AIM Italia to 153.
In the placement phase, Ulisse Biomed S.p.A. raised €4.5 million, excluding the potential exercise of an over-allotment option. In case of the full exercise of the over-allotment option, the total amount raised will be €5 million. The free float at the time of admission was 31,82% and the market capitalisation at IPO was €14.5 million.
Matteo Petti, CEO, Ulisse Biomed S.p.A., said: "The listing today will allow us to finance our growth and bring to the market the products that are on our technological platforms, enhancing, in this way, our visibility, standing and confirming our independent growth. We will continue to focus our efforts in order to make personalised treatments an affordable reality to everyone, using the countless opportunities offered by the use of DNA, for the benefit of our company and our shareholders. We present ourselves to the market with the structure of a public company, hoping to meet expectations with positive results and the trust that has been placed in us."
Matteo Petti, CEO of Ulisse Biomed S.p.A. rang the bell during the market open ceremony this morning to celebrate the Initial Public Offering of the company.
Ulisse Biomed S.p.A. Ulisse Biomed S.p.A. is an healthcare biotech company operating in the diagnostics, theranostics and therapeutics with the mission to develop innovative solutions in these fields. The company has three proprietary technology platforms capable of generating innovative and competitive products: Sagitta (molecular diagnostics), NanoHybrid (theranostics and diagnostics) and Aptavir (therapeutics). UBM owns a portfolio of intellectual properties made of 8 international patent applications that cover the three technology platforms (3 related to Sagitta, 2 related to NanoHybrid, 1 related to Aptavir and 2 transversal to the three platforms), two of them are granted in Italy and in Europe.